I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Senior Engineer - Product Development Engineer, Automatic Testing

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's
Haifa, Israel
In Person
QA & TestingTest Automation Engineering

About the job

Requirements
  • A bachelor's degree in Computer Science, Software Engineering, Information System, or a related field is required.
  • At least 5 years of experience as a Software Engineer, Systems Engineer, Test Automation Engineer, Test Engineer, or in a related technical role is required.
  • At least 3 years of hands-on experience developing and maintaining automated test solutions is required.
  • Experience in a regulated industry is required; medical devices, healthcare, or life sciences experience is preferred.
  • Experience throughout the product development lifecycle, including verification and validation activities, is required.
  • Strong experience with object-oriented programming is required; C# is preferred.
  • Experience with automation tools such as Ranorex or equivalent platforms is required.
  • Experience developing automated testing solutions and frameworks is required.
  • A solid understanding of software testing methodologies and verification principles is required.
  • An understanding of requirements management, defect tracking, configuration management, and software verification and validation processes is required.
  • Experience writing test cases, protocols, and traceability documentation is required.
  • The ability to troubleshoot complex technical issues and identify root causes is required.
  • Proficient written and verbal English communication is required.
Responsibilities
  • Analyze and interpret product, system, and software requirements.
  • Design automated test solutions that verify functional, performance, and system-level requirements.
  • Develop, maintain, and improve automated test scripts and supporting automation frameworks.
  • Participate in architecture and design reviews for automation solutions.
  • Perform code reviews and ensure compliance with software development best practices.
  • Create and maintain automation-related documentation.
  • Contribute to automation strategy and continuous improvement initiatives.
  • Execute automated test suites and evaluate test outcomes.
  • Investigate test failures and differentiate between product defects, environmental issues, and script-related problems.
  • Document and communicate defects using the Defect Management System.
  • Collaborate with Software Engineering, Systems Engineering, Quality, and Product Management teams to resolve issues.
  • Provide analysis and recommendations based on test results and trends.
  • Develop and maintain test cases, protocols, and automated verification procedures.
  • Ensure traceability between requirements, risks, and verification activities.
  • Support design verification and validation efforts.
  • Execute manual testing when automation is not feasible or practical.
  • Review requirements and test coverage for completeness and quality.
  • Mentor and support Engineer I and Engineer II team members.
  • Promote automation best practices and coding standards.
  • Identify opportunities to improve test efficiency, coverage, and maintainability.
  • Participate in continuous improvement activities within the development lifecycle.
  • Communicate business-related issues and opportunities with management.
  • Follow applicable procedures, policies, and guidelines.
  • Ensure compliance with quality system and regulatory requirements.
  • Perform other duties assigned as needed by management.
Desired Qualifications
  • Experience working in Agile development environments is an advantage.
  • ISTQB certification is an advantage.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.